Ominsky M, Boyce RG, Kosteniuk P, et al 2013 Nf1 Continuous modeling-based bone formation: A novel mechanism that could explain the sustained increases.

Slides:

Advertisements

Similar presentations

Chapter 68 Chapter 68 Fracture Risk Assessment: The Development and Application of FRAX ® Copyright © 2013 Elsevier Inc. All rights reserved.

Advertisements

Chapter 85 Chapter 85 Parathyroid Hormone Treatment for Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Bone Quality PART 2 Damage Accumulation Degree of Mineralization Biomechanics.

Bone Quality PART 3 Collagen/Mineral Matrix Conclusions Supplemental Slides.

Osteoporosis Reggie Williams Elissa Kordulak Adam Moreton.

Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

ECTS symposium 5 Anabolic treatment of osteoporosis.

Denosumab NICE technology appraisal guidance 204 October 2010.

Bone Turnover Suppression Based on an ASBMR/ECTS Clincal Debate “Too Much Suppression of Turnover Is Bad for Bone” Co-Chairs: Socrates Papapoulos, Douglas.

June 2004 Bone Quality June 2004 A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue,

Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

WHAT IS Osteoporosis ? Osteoporosis is a common disease in the whole world, the danger in that disease is that you can't figure out if you have it early,

Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.

Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

UNIVERSITY of DERBY Implementing TA 161 and 204 in the real world Dr. Jonathan Bayly Visiting Fellow, University of Derby.

Chapter 54 Chapter 54 HIV and Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures by Tamara D. Rozental, Eric C. Makhni, Charles S. Day, and Mary L.

Chapter 41: Role of Sex Steroids in the Pathogenesis of Osteoporosis Matthew T. Drake and Sundeep Khosla.

Moji Saberin-Williams, M.D. Paoli Hospital Obstetrician/Gynecologist

Chapter 34: Biochemical Markers of Bone Turnover in Osteoporosis Pawel Szulc and Pierre D. Delmas.

Clinical use of RANKL Inhibitor in Osteoporosis

Osteopenia and Osteoporosis

Copyright © 2015 by the American Osteopathic Association.

(The data are from Southard RN, et al

Anti-Osteoporotic drugs Old & New

OSTEOPOROSIS Florence TREMOLLIERES, MD, PhD

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Chapter 38: Epidemiology of Osteoporotic Fractures

Copyright © 2015 by the American Osteopathic Association.

Chapter 61: Transplantation Osteoporosis

Algorithm of the approach to the diagnosis and treatment of children with fractures due to osteoporosis. BMD, bone mineral density; GC, glucocorticoids;

THE EFFECTIVENESS OF ANNUAL ZOLEDRONIC ACID INFUSION VERSUS ORAL BISPHOSPHONATE: A MODELLING APPROACH Terence Ong1, 2, Matthey Jones3, Opinder Sahota1.

Goal-directed Treatment for Osteoporosis

Treatment Of Osteoporosis

Health Science 1 Project

The Future of Osteoporosis: Improving Care Along the Way

Incidence rates for the three common osteoporotic fractures

11/7/2018 OSTEOPOROSIS.

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

Diabetes and Bone: the model of GIO

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

The erlangen fitness osteoporosis prevention study: a controlled exercise trial in early postmenopausal women with low bone density—first-year results

J Bone Miner Res 2015;30:1553 (Fig. 1)

RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer Matthew R. Smith European Urology Supplements

Treatment Options for Osteoporosis

1/3/2019 OSTEOPOROSIS.

Vert Non-Vert Hip ** ** Zoledronic Acid3 Zoledronic Acid4 Denosumab5

Bisphosphonate exposure and Atypical Femoral Fractures

Image with permission from PR Buenzli and NA Sims.

Lippuner et al Osteoporos Int 2011;22:2487

Bone 2013; doi: /j.bone (Fig. 1)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial by Ersi Voskaridou,

J Bone Miner Res 2013; 28:2266 (Fig. 2)

Osteoporos Int 2015;26:2243 (Fig. 2)

Bone 2013;56:23 (Fig. 1) Reproduced from Bone, 56:23-9, Copyright (2013), with permission from Elsevier.

Opportunistic Osteoporosis Screening at Routine Abdominal and Thoracic CT: Normative L1 Trabecular Attenuation Values in More than Adults Routine.

J Bone Miner Res 2013; doi: /jbmr.2072 (Fig. 1)

Disordered Eating, Menstrual Disturbances, and Low Bone Mineral Density in Dancers: A Systematic Review Cesar A. Hincapié, DC, MHSc, J. David Cassidy,

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Bone 2014;61:191 (Fig. 2) Reproduced from Bone, 61: , Copyright (2014), with permission from Elsevier.

JBMR 2012;doi:[ /jbmr.1760] (Fig. 3A)

Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.

Glucocorticoid-induced osteoporosis: An update on effects and management Bjoern Buehring, MD, Ravi Viswanathan, MD, Neil Binkley, MD, William Busse, MD

Bone 2014;69C:89 (Fig. 2) Reproduced from Bone, 69C:89-97, Copyright (2014), with permission from Elsevier.

J Bone Miner Res 2014;doi: /jbmr.2325 (Fig. 2)

Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.

Subjects Randomized to Denosumab or Bisphosphonate Therapy

Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline use of glucocorticoid.

Presentation transcript:

Ominsky M, Boyce RG, Kosteniuk P, et al 2013 Nf1 Continuous modeling-based bone formation: A novel mechanism that could explain the sustained increases in hip bone mineral density (BMD) with denosumab treatment. J Bone Miner Res 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=89fd1f4a-ff73-4a62-accc-d9ae7dac6e22. Accessed November 15, 2013. Reproduced with permission of the American Society of Bone and Mineral Research.

Zebaze RM, Libanati C, McClung MR, et al 2013 Denosumab reduces hip cortical porosity in women with osteoporosis. J Bone Miner Res 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=d383c95f-4672-4dc0-8685-dda837df4d90. Accessed November 15, 2013. Reproduced with permission of the American Society of Bone and Mineral Research.

Leder B, Uihlein A, Tsai J, et al 2013 The DATA Extension Study: 2 years of combined denosumab and teriparatide in postmenopausal women with osteoporosis: A randomized controlled trial. J Bone Miner Res 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=c6aff623-b458-4737-8c3f-2381c0a9217e. Accessed November 15, 2013. Reproduced with permission of the American Society of Bone and Mineral Research.

Papapoulos S, Lippuner K, Roux C, et al 2013 Eight years of denosumab treatment in postmenopausal women with osteoporosis: Results from the first five years of the FREEDOM Extension. J Bone Miner Res 28 (Suppl 1). Available at http://www.asbmr.org/asbmr-2013-abstract-detail?aid=4e003dea-3d2d-4ae5-9f4e-777f089e5876. Accessed November 15, 2013. Reproduced with permission of the American Society of Bone and Mineral Research.